RADNOR, Pa., June 03, 2023 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Southern District of Florida against Icahn Enterprises L.P. (“Icahn Enterprises”) (NASDAQ:IEP). The action charges Icahn Enterprises with […]
The clinical trial of the personalized cancer vaccine EVX-01 met its primary endpoints of safety and tolerabilityPositive clinical responses were reported in 8 out of 12 EVX-01 treated patientsHigh-quality neoantigens, predicted by AI technology, were associated with longer progression-free survivalStrong vaccine-specific immune responses were induced in all 12 EVX-01 treated patients Higher EVX-01 dose induced a […]
NEW YORK, June 03, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues its investigation of potential securities claims on behalf of shareholders of Fox Corporation (NASDAQ: FOX, FOXA) resulting from allegations that FOX may have issued materially misleading business information to the investing public. The prospective class includes […]
Additional long-term data from the TRiMM-2 study in patients receiving talquetamab and DARZALEX® (daratumumab) subcutaneous (SC) formulation combination biweekly regimen showed an overall response rate of more than 80 percent1,2,3 BEERSE, BELGIUM, June 03, 2023 (GLOBE NEWSWIRE) -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today updated results from the pivotal Phase 1/2 MonumenTAL-1 […]
- Consistent with data shared in January 2023, the presentation at ASCO 2023 highlights data from the Phase 1 dose-expansion study for luveltamab tazevibulin, or luvelta, in ovarian cancer, demonstrating that FolRα-selected patients, who represent 80% of the patient population, experienced substantial clinical benefit - - REFRaME-O1, the Phase 2/3 pivotal study of luvelta for […]
NEW YORK, June 03, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Wheels Up Experience Inc. (NYSE: UP) between November 9, 2022 and March 31, 2023, both dates inclusive (the “Class Period”), of the important June 20, 2023 lead plaintiff deadline in the securities […]
NEW YORK, June 03, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Virtu Financial, Inc., (NASDAQ: VIRT) between March 1, 2019 and April 28, 2023, both dates inclusive (the “Class Period”) of the important July 18, 2023 lead plaintiff deadline. SO WHAT: If you […]
BEERSE, BELGIUM, June 03, 2023 (GLOBE NEWSWIRE) -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the first results from the Phase 1b RedirecTT-1 study of TECVAYLI®▼ (teclistamab), a BCMAxCD3 bispecific antibody, and talquetamab, a GPRC5DxCD3 bispecific antibody, showing a high overall response rate (ORR) among patients with relapsed or refractory multiple myeloma […]
NEW YORK, June 03, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of PDD Holdings Inc. f/k/a Pinduoduo Inc. (NASDAQ: PDD) resulting from allegations that PDD may have issued materially misleading business information to the investing public. SO WHAT: If […]
- Data presented at ASCO annual meeting demonstrate 55% Disease Control Rate (DCR) in heavily pre-treated GIST patients, including 100% DCR and 17% overall response rate (ORR) in efficacy evaluable 2nd-line GIST patients; data immature to estimate progression free survival (PFS) - Combination of bezuclastinib and sunitinib is well-tolerated and consistent with published sunitinib monotherapy safety […]
